Do go read it all at FierceBiotech — but good news for Kenilworth’s diversifying pipeline efforts:
. . . .Launched in 2009 with backing from Third Rock and Pappas, with Kevin Starr taking the chairman’s role, San Mateo, CA-based Afferent specialized in targeting the P2X3 receptor as a pathway to treating a variety of neurogenic conditions. Hitting this target should damp down a process that oversensitizes certain sensory nerves. . . .
Keep it spinning in good karma, one and all!